H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference Date/Time Tuesday, February 25, 2025, at 11:00 a.m. ET. Webcast Link https://journey.ct.events/view/acb6057e-9d9b-427e-b490-eaf85a5c2910 ...

H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Protagonist Therapeutics (PTGX) to $54 from $50 and keeps a Buy rating ...

HC Wainwright reissued their buy rating on shares of Benitec Biopharma (NASDAQ:BNTC – Free Report) in a research report sent ...

HC Wainwright reiterated their neutral rating on shares of Ardelyx (NASDAQ:ARDX – Free Report) in a research report sent to ...

On Monday, H.C. Wainwright reaffirmed a Buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) with a $36.00 price target. The stock, currently trading at $5.97, has seen significant ...

On Monday, H.C. Wainwright reaffirmed a Buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) with a $36.00 price target. The stock, currently trading at $5.97, has seen significant ...

Fintel reports that on February 7, 2025, HC Wainwright & Co. initiated coverage of Vertical Aerospace (NYSE:EVTL) with a Buy recommendation. Analyst Price Forecast Suggests 94.58% Upside As of ...

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (BRSE:1CG) with a Buy recommendation. There are 575 funds or institutions reporting positions ...

On January 31, the company announced that H.C. Wainwright & Co. has initiated coverage on it with a “Buy” rating and a 12-month price target of $16 per share. The report highlights several ...

H.C. Wainwright estimates Knightscope’s near-term market opportunity at $4 billion, with long-term industry potential exceeding $41 billion in recurring revenue. "Following strategic corporate ...